Regina R. Sarmanayeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Regina R. Sarmanayeva has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Guzal R. Abuzarova
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
18 shared publications - S. V. Kuznetcov
P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
7 shared publications - Yu.V. Brazhnikova
P. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
6 shared publications - Galina S. Alekseeva
National Medical Research Radiological Centre
5 shared publications - Natalya M. Bychkova
Hertsen Moscow Scientific Researh Institute of Oncology – Branch of the National Medical Research Radiological Centre
5 shared publications - Artem Rubenovich Gevorkov
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre, Ministry of Health of Russia
3 shared publications
Latest Publications
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 13-21
Efficacy and safety of Tafalgin in palliative patients with chronic pain: results of a multicenter NIKITA-P study
Objective. To evaluate the efficacy and safety of the peptide analgesic Tafalgin in palliative patients with chronic pain syndrome. Material and methods. A multicenter (19 centers) non-interventional clinical trial of NIKITA-Palliative was conducted in 188 patients, mainly with oncological (84.5%) chronic pain syndrome (CPS) and comorbid pathology. Results. The initial pain intensity (IP) was 7.18—8.11 NRS points (from 0 to 10), 15 minutes after injection there was a statistically significant decrease in pain at rest and during movement (p<0.0001); after 1 hour, IP decreased below the level of <3 points. Maximal analgesic effect was achieved after an average of 45 minutes, and the duration of anesthesia was 8.5 hours. The proportion of patients who responded to Tafalgin therapy was 94.1%, and 72.3% of patients achieved a sufficient level of anesthesia. During treatment, there was a statistically significant improvement in quality of life: a decrease in general weakness, irritability, daytime sleepiness, an improvement in nighttime sleep and appetite (p<0.0001), and an improvement in the quality of nighttime sleep. The majority of doctors (69.7%) and patients (66.6%) rated the effectiveness of Tafalgin therapy as good or excellent. Adverse reactions (AR) were reported in 14 of 188 patients (7.4%), with a total of 26 AR. The most common were blurred consciousness (2.6%), dizziness (2.1%) and dry mouth (1.6%). All AR were mild or moderate, no serious adverse reactions were recorded, and all episodes were treated without consequences. Conclusion. Tafalgin demonstrated an effective reduction in pain intensity lasting 8.5 hours against the background of a favorable safety profile in palliative patients with chronic pain syndrome despite concomitant pathology. The drug can be considered as an effective component of analgesic therapy of severe pain, including in combination with non-narcotic, narcotic and adjuvant analgesics.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 13-21
Efficacy and safety of Tafalgin in palliative patients with chronic pain: results of a multicenter NIKITA-P study
Objective. To evaluate the efficacy and safety of the peptide analgesic Tafalgin in palliative patients with chronic pain syndrome. Material and methods. A multicenter (19 centers) non-interventional clinical trial of NIKITA-Palliative was conducted in 188 patients, mainly with oncological (84.5%) chronic pain syndrome (CPS) and comorbid pathology. Results. The initial pain intensity (IP) was 7.18—8.11 NRS points (from 0 to 10), 15 minutes after injection there was a statistically significant decrease in pain at rest and during movement (p<0.0001); after 1 hour, IP decreased below the level of <3 points. Maximal analgesic effect was achieved after an average of 45 minutes, and the duration of anesthesia was 8.5 hours. The proportion of patients who responded to Tafalgin therapy was 94.1%, and 72.3% of patients achieved a sufficient level of anesthesia. During treatment, there was a statistically significant improvement in quality of life: a decrease in general weakness, irritability, daytime sleepiness, an improvement in nighttime sleep and appetite (p<0.0001), and an improvement in the quality of nighttime sleep. The majority of doctors (69.7%) and patients (66.6%) rated the effectiveness of Tafalgin therapy as good or excellent. Adverse reactions (AR) were reported in 14 of 188 patients (7.4%), with a total of 26 AR. The most common were blurred consciousness (2.6%), dizziness (2.1%) and dry mouth (1.6%). All AR were mild or moderate, no serious adverse reactions were recorded, and all episodes were treated without consequences. Conclusion. Tafalgin demonstrated an effective reduction in pain intensity lasting 8.5 hours against the background of a favorable safety profile in palliative patients with chronic pain syndrome despite concomitant pathology. The drug can be considered as an effective component of analgesic therapy of severe pain, including in combination with non-narcotic, narcotic and adjuvant analgesics.
- Open Access
- 21 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 4,p. 68-76
Sublingual Bupraxon Tablets in Cancer Patients: Initial Results from Real-World Clinical Practice
Introduction. Adequate pain management in cancer patients remains a serious challenge. Long-term and uncontrolled use of NSAIDs is associated with a high risk of complications, while the use of opioids is often limited by their adverse effects, particularly constipation, and the potential risk of diversion. Combination drugs such as Bupraxon (buprenorphine + naloxone) represent a promising alternative.Objective. To present to the medical community the initial clinical experience with the domestic combined drug Bupraxon for sublingual administration in cancer patients with chronic pain syndrome (CPS).Methods and materials. This paper presents the results of a post-marketing observational study involving 22 cancer patients with CPS, as well as two detailed clinical case reports. The analgesic efficacy, time to onset and duration of action, tolerability, and safety of the drug were assessed in a real-world clinical setting.Results. Bupraxon was shown to provide effective control of moderate to severe intensity pain. The onset of action was observed within 30–45 minutes, and the duration of analgesia was 4–8 hours. For 12 out of 22 patients, an effective dose was titrated within 2–3 days. The drug was well-tolerated, with no significant gastrointestinal adverse events (specifically, no constipation) and no withdrawal syndrome following short-term use. The combination with naloxone enhances narcological safety by reducing the risk of abuse.Conclusions. Bupraxon is an effective and safe option for the management of CPS in cancer patients, particularly in those at risk of bowel obstruction. Its non-invasive form, controllable analgesia, and favorable safety profile make it a promising alternative to other opioid analgesics. Further comparative studies are required for a comprehensive assessment of the drug's potential.
- 21 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 4,p. 68-76
Open AccessSublingual Bupraxon Tablets in Cancer Patients: Initial Results from Real-World Clinical Practice
Introduction. Adequate pain management in cancer patients remains a serious challenge. Long-term and uncontrolled use of NSAIDs is associated with a high risk of complications, while the use of opioids is often limited by their adverse effects, particularly constipation, and the potential risk of diversion. Combination drugs such as Bupraxon (buprenorphine + naloxone) represent a promising alternative.Objective. To present to the medical community the initial clinical experience with the domestic combined drug Bupraxon for sublingual administration in cancer patients with chronic pain syndrome (CPS).Methods and materials. This paper presents the results of a post-marketing observational study involving 22 cancer patients with CPS, as well as two detailed clinical case reports. The analgesic efficacy, time to onset and duration of action, tolerability, and safety of the drug were assessed in a real-world clinical setting.Results. Bupraxon was shown to provide effective control of moderate to severe intensity pain. The onset of action was observed within 30–45 minutes, and the duration of analgesia was 4–8 hours. For 12 out of 22 patients, an effective dose was titrated within 2–3 days. The drug was well-tolerated, with no significant gastrointestinal adverse events (specifically, no constipation) and no withdrawal syndrome following short-term use. The combination with naloxone enhances narcological safety by reducing the risk of abuse.Conclusions. Bupraxon is an effective and safe option for the management of CPS in cancer patients, particularly in those at risk of bowel obstruction. Its non-invasive form, controllable analgesia, and favorable safety profile make it a promising alternative to other opioid analgesics. Further comparative studies are required for a comprehensive assessment of the drug's potential.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 73-77
New analgesics in oncology. Tafalgin employed as an alternative to opioid analgesics
The publication presents data on new analgesics that could serve as an alternative to opioids, having a comparable analgesic effect, but with a lower risk of serious adverse events. Tafalgin is a selective agonist of the m1-opioid receptors, due to which it has a decend analgetic effect comparable to opioid analgesics with a more favorable safety profile, which has been demonstrated both in clinical studies and in real clinical practice. Tafalgin has been introduced into clinical practice relatively recently, so there are few publications revealing the specifics of its use in various clinical situations. The presented clinical observation describes the possibility of taking Tafalgin not only as a drug for the treatment of acute or breakthrough pain, but also as a basic analgesic for intensity pain syndromes, especially in situations where taking opioid analgesics is undesirable or impossible for any reason.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 73-77
New analgesics in oncology. Tafalgin employed as an alternative to opioid analgesics
The publication presents data on new analgesics that could serve as an alternative to opioids, having a comparable analgesic effect, but with a lower risk of serious adverse events. Tafalgin is a selective agonist of the m1-opioid receptors, due to which it has a decend analgetic effect comparable to opioid analgesics with a more favorable safety profile, which has been demonstrated both in clinical studies and in real clinical practice. Tafalgin has been introduced into clinical practice relatively recently, so there are few publications revealing the specifics of its use in various clinical situations. The presented clinical observation describes the possibility of taking Tafalgin not only as a drug for the treatment of acute or breakthrough pain, but also as a basic analgesic for intensity pain syndromes, especially in situations where taking opioid analgesics is undesirable or impossible for any reason.
- Open Access
- 18 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 65-78
Acute pain in oncology: specific features and treatment options. What is new?
Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics.Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”.Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients.Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.
- 18 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 65-78
Open AccessAcute pain in oncology: specific features and treatment options. What is new?
Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics.Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”.Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients.Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (6)
Use of a new tetrapeptide analgesic at the stages of antitumor therapy
Objective. To present the interim results of the Observational Program for monitoring the effectiveness and safety of Tafalgin in real clinical practice “NIKITA” in a group of patients receiving anticancer treatment. Material and methods. The analysis of intermediate data in separate groups of patients receiving radiation therapy and chemotherapy (RT and ChT) was carried out. The proportion of patients who responded to therapy after the first injection of Tafalgin was revealed, the analgesic effect of Tafalgin was assessed: the average time of onset and duration of analgesia, the effectiveness of anesthesia on a 10-point numerological evaluation scale (NRS); assessment of the dynamics of physical activity on the ECOG scale, the quality of night sleep, assessment of doctor satisfaction and safety of Tafalgin. Results. In the RT group, there was a statistically significant decrease in pain intensity to 3.2±2.0 on the NRS (p<0.001) 15 min. after subcutaneous injection 4 mg of Tafalgin and — 2.0± 1.5 after 1 hour. The median time to achieve the maximum analgesic effect was 13.5 (10; 30) min., and the median time to maintain the achieved analgesic effect was 360 (300; 660) min. The proportion of patients with an acceptable level of pain relief was achieved in 85% of patients. In the ChT group maximum analgesic effect was 2.4±1.7 after injection, the median time to achieve the maximum effect was 40 (30; 60) min., and to maintain the achieved analgesic effect was 240 (180; 420) min. The proportion of patients with an acceptable level of analgesia was 72.9% of patients. Side effects prevailed in ChT group and were detected in 38.9%, in the in RT group it was 15%. Severity of side effects were mild or moderate, resolved independently within 30—60 minutes. Satisfaction with the analgesic effect of Tafalgin was high in patients of both groups and in research physicians. Conclusion. Tafalgin has a strong analgesic efficiency and an acceptable security profile. Tafalgin may be recommended for use in broad clinical practice in oncology in radiation and drug therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (6)
Use of a new tetrapeptide analgesic at the stages of antitumor therapy
Objective. To present the interim results of the Observational Program for monitoring the effectiveness and safety of Tafalgin in real clinical practice “NIKITA” in a group of patients receiving anticancer treatment. Material and methods. The analysis of intermediate data in separate groups of patients receiving radiation therapy and chemotherapy (RT and ChT) was carried out. The proportion of patients who responded to therapy after the first injection of Tafalgin was revealed, the analgesic effect of Tafalgin was assessed: the average time of onset and duration of analgesia, the effectiveness of anesthesia on a 10-point numerological evaluation scale (NRS); assessment of the dynamics of physical activity on the ECOG scale, the quality of night sleep, assessment of doctor satisfaction and safety of Tafalgin. Results. In the RT group, there was a statistically significant decrease in pain intensity to 3.2±2.0 on the NRS (p<0.001) 15 min. after subcutaneous injection 4 mg of Tafalgin and — 2.0± 1.5 after 1 hour. The median time to achieve the maximum analgesic effect was 13.5 (10; 30) min., and the median time to maintain the achieved analgesic effect was 360 (300; 660) min. The proportion of patients with an acceptable level of pain relief was achieved in 85% of patients. In the ChT group maximum analgesic effect was 2.4±1.7 after injection, the median time to achieve the maximum effect was 40 (30; 60) min., and to maintain the achieved analgesic effect was 240 (180; 420) min. The proportion of patients with an acceptable level of analgesia was 72.9% of patients. Side effects prevailed in ChT group and were detected in 38.9%, in the in RT group it was 15%. Severity of side effects were mild or moderate, resolved independently within 30—60 minutes. Satisfaction with the analgesic effect of Tafalgin was high in patients of both groups and in research physicians. Conclusion. Tafalgin has a strong analgesic efficiency and an acceptable security profile. Tafalgin may be recommended for use in broad clinical practice in oncology in radiation and drug therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (5)
Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a significant problem in oncology, which greatly worsens the quality of life of patients and is the reason for the reduction or cancellation of cancer therapy. The review presents the pathophysiological features of the development of CIPN, describes the features of the diagnosis of CIPN, risk factors for its development, prevention and treatment. In addition to the only currently approved ASCO duloxetine, the results of clinical studies confirming the therapeutic effect of a central analgesic with a mixed mechanism of action, tapentadol, comparable to duloxetine, are presented
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (5)
Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a significant problem in oncology, which greatly worsens the quality of life of patients and is the reason for the reduction or cancellation of cancer therapy. The review presents the pathophysiological features of the development of CIPN, describes the features of the diagnosis of CIPN, risk factors for its development, prevention and treatment. In addition to the only currently approved ASCO duloxetine, the results of clinical studies confirming the therapeutic effect of a central analgesic with a mixed mechanism of action, tapentadol, comparable to duloxetine, are presented
- Open Access
- 11 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (3) , 43-50
Orofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.
- 11 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (3) , 43-50
Open AccessOrofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.
- Open Access
- 25 November 2022
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (3) , 313-318
A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain
In the Russian Federation, tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycine amide (Tafalgin), a novel analgesic, selective agonist of 1-opioid receptors, was developed and approved in 2022. The article presents the first experience of the successful use of Tafalgin in treating chronic pain in a cancer patient with poor tolerance to traditional opioids (tramadol, tapentadol, morphine). At baseline, pain severity, according to the Neurological Rating Scale (NRS), was 57 points at rest and up to 9 points in motion out of the maximum 10. The combination of 400 mg/day of tramadol with gabapentin and a non-steroidal anti-inflammatory drug was ineffective; 400 mg/day of tapentadol in combination with gabapentin and a non-steroidal anti-inflammatory drug also was ineffective. Morphine tablets 60 mg/day were effective (NRS score of 23), but unrelenting nausea and vomiting were unmanageable and significantly reduced quality of life. Reducing the dose of oral morphine to 20 mg/day mitigated adverse events but reduced the effectiveness of pain relief (resting NRS score of 4 points). Tafalgin 4 mg subcutaneously BID, then TID reduced the pain severity to an average daily NRS score of 1.22 over the first 3 days of treatment with no adverse events. Sleep, appetite, and physical activity improved. The patient received Tafalgin for 84 days, and she gained 5 kg due to improved nutrition during that time. The drug is comparable in efficacy to morphine and is associated with fewer adverse events. A limitation to widespread use is the availability of a formulation for subcutaneous injection only.
- 25 November 2022
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (3) , 313-318
Open AccessA clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain
In the Russian Federation, tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycine amide (Tafalgin), a novel analgesic, selective agonist of 1-opioid receptors, was developed and approved in 2022. The article presents the first experience of the successful use of Tafalgin in treating chronic pain in a cancer patient with poor tolerance to traditional opioids (tramadol, tapentadol, morphine). At baseline, pain severity, according to the Neurological Rating Scale (NRS), was 57 points at rest and up to 9 points in motion out of the maximum 10. The combination of 400 mg/day of tramadol with gabapentin and a non-steroidal anti-inflammatory drug was ineffective; 400 mg/day of tapentadol in combination with gabapentin and a non-steroidal anti-inflammatory drug also was ineffective. Morphine tablets 60 mg/day were effective (NRS score of 23), but unrelenting nausea and vomiting were unmanageable and significantly reduced quality of life. Reducing the dose of oral morphine to 20 mg/day mitigated adverse events but reduced the effectiveness of pain relief (resting NRS score of 4 points). Tafalgin 4 mg subcutaneously BID, then TID reduced the pain severity to an average daily NRS score of 1.22 over the first 3 days of treatment with no adverse events. Sleep, appetite, and physical activity improved. The patient received Tafalgin for 84 days, and she gained 5 kg due to improved nutrition during that time. The drug is comparable in efficacy to morphine and is associated with fewer adverse events. A limitation to widespread use is the availability of a formulation for subcutaneous injection only.
- Open Access
- 19 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 147-156
Projection into the future: combination of orphenadrine and diclofenac in patients with bone metastases
Introduction. Radiation therapy is an effective method of treating pain in patients with bone metastases, but during radiotherapy there is often an increase in pain. The presence of a new drug containing a combination of orphenadrine and diclofenac in oncologists expands the possibilities of analgesia.Aim. To evaluate the efficacy and safety of the use of a fixed combination of diclofenac and orphenadrine in patients with pain due to metastatic bone damage during radiotherapy.Materials and methods. The patients were randomized into two groups: the first group (n = 30) received the drug Neodolpasse intravenously once a day for two days; the second - 2 times a day (n = 30) - 2 days. Efficacy was evaluated based on the following measurements: intensity of pain by NRS immediately after administration of the drug, after 30 minutes, after 1, 2, 4 and 24 hours, the dynamics of daily doses of analgesics.Results and discussion. In group 1, a meaningful decrease in pain intensity (p < 0.05) from 48.7 ± 10.6 mm to 26.8 ± 10.7 mm was achieved 30 minutes after the completion of infusion. The pain intensity measured by the Numeric Rating Scale (NRS) reached its minimum value 2 hours after the completion of infusion (22.5 ± 12.0 mm). In group 2, the pain intensity decreased 30 minutes after the completion of infusion, a meaningful decrease (p < 0.05) in pain intensity was achieved from 56.5 ± 9.8 mm to 34.0 ± 10.5 mm, and up to 29.8 ± 10.2 mm after the second dose. The pain intensity decreased by 45.9% in group 1 and by 47.9% in group 2 towards the end of the Neodolpasse therapy cycle. During the study, two mild to moderate adverse events (nausea, drop in blood pressure) that did not require any significant drug therapy were observed.Conclusion. The results of the study confirm that the use of the drug according to the proposed method is a safe and effective way of treating pain syndrome during radiotherapy in patients with metastatic bone damage.
- 19 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 147-156
Open AccessProjection into the future: combination of orphenadrine and diclofenac in patients with bone metastases
Introduction. Radiation therapy is an effective method of treating pain in patients with bone metastases, but during radiotherapy there is often an increase in pain. The presence of a new drug containing a combination of orphenadrine and diclofenac in oncologists expands the possibilities of analgesia.Aim. To evaluate the efficacy and safety of the use of a fixed combination of diclofenac and orphenadrine in patients with pain due to metastatic bone damage during radiotherapy.Materials and methods. The patients were randomized into two groups: the first group (n = 30) received the drug Neodolpasse intravenously once a day for two days; the second - 2 times a day (n = 30) - 2 days. Efficacy was evaluated based on the following measurements: intensity of pain by NRS immediately after administration of the drug, after 30 minutes, after 1, 2, 4 and 24 hours, the dynamics of daily doses of analgesics.Results and discussion. In group 1, a meaningful decrease in pain intensity (p < 0.05) from 48.7 ± 10.6 mm to 26.8 ± 10.7 mm was achieved 30 minutes after the completion of infusion. The pain intensity measured by the Numeric Rating Scale (NRS) reached its minimum value 2 hours after the completion of infusion (22.5 ± 12.0 mm). In group 2, the pain intensity decreased 30 minutes after the completion of infusion, a meaningful decrease (p < 0.05) in pain intensity was achieved from 56.5 ± 9.8 mm to 34.0 ± 10.5 mm, and up to 29.8 ± 10.2 mm after the second dose. The pain intensity decreased by 45.9% in group 1 and by 47.9% in group 2 towards the end of the Neodolpasse therapy cycle. During the study, two mild to moderate adverse events (nausea, drop in blood pressure) that did not require any significant drug therapy were observed.Conclusion. The results of the study confirm that the use of the drug according to the proposed method is a safe and effective way of treating pain syndrome during radiotherapy in patients with metastatic bone damage.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (5)
The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial
Необходимость создания новых безопасных препаратов для адекватного контроля боли у онкологических пациентов очевидна. Одним из направлений является поиск селективных молекул, взаимодействующих с μ1-опиоидными рецепторами, лишенных многих побочных эффектов опиоидов. Такой препарат создан в России — это Тафалгин, при этом он не имеет зарубежных аналогов. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить эффективность и безопасность анальгетика Тафалгина у онкологических пациентов с хроническим болевым синдромом (ХБС), подтвердить гипотезу о неменьшей эффективности Тафалгина в сравнении с морфином. МАТЕРИАЛ И МЕТОДЫ На базе 5 клинических центров проведено открытое сравнительное многоцентровое рандомизированное клиническое исследование III фазы по изучению эффективности и безопасности Тафалгина у онкологических пациентов с ХБС. Пациенты рандомизированы в две группы: 1-я группа (n=120) получала только Тафалгин подкожно; 2-я группа (n=59) — таблетки морфина 28 дней (период 1) и далее Тафалгин 28 дней (период 2). Первичной конечной точкой эффективности была частота сохранения ответа на обезболивающую терапию к 28-му дню. ХБС оценивали по цифровой рейтинговой шкале (NRS 0/10 баллов); по 5-балльной шкале Лайкерта для пациентов и врачей; по опроснику качества жизни SF-36. Анализ безопасности проводили на основании оценки частоты и выраженности нежелательных явлений (НЯ). РЕЗУЛЬТАТЫ Всего обследовано 179 пациентов (популяция ITT); завершили обследование 143 пациента (популяция PP). В 1-й группе доля пациентов с сохранением ответа на обезболивающую терапию к 28-му дню составила 98,97%, во 2-й группе — 100,00% (p=0,6783) для популяции РР. Для популяции ITT: в 1-й группе доля пациентов с сохранением ответа на обезболивающую терапию к 28-му дню была 84,17%, во 2-й группе — 88,14% (p=0,4787). Не выявлено случаев неэффективной терапии Тафалгином. Среднее значение NRS в популяция PP в начале терапии составило 0,42±0,48 и 0,30±0,47 балла в 1-й и 2-й группах (p=0,1250); к 28-му дню — 0,38±0,44 и 0,28±0,30 балла в этих группах (p=0,3472). В популяции ITT: NRS исходно составил 0,53±0,61 и 0,51±0,81 балла в 1-й и 2-й группах, (p=0,3519); к 28-му дню — 0,54±0,81 и 0,41±0,50 балла соответственно, (p=0,4536). После перевода пациентов с морфина на Тафалгин сохранился адекватный контроль боли через 56 и 84 дня терапии. На фоне приема Тафалгина определялась меньшая частота возникновения НЯ. ЗАКЛЮЧЕНИЕ Тафалгин оказывает выраженное обезболивающее действие, не уступающее морфину при лечении онкологического ХБС, имеет благоприятный профиль безопасности и меньшую частоту НЯ относительно морфина.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (5)
The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial
Необходимость создания новых безопасных препаратов для адекватного контроля боли у онкологических пациентов очевидна. Одним из направлений является поиск селективных молекул, взаимодействующих с μ1-опиоидными рецепторами, лишенных многих побочных эффектов опиоидов. Такой препарат создан в России — это Тафалгин, при этом он не имеет зарубежных аналогов. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить эффективность и безопасность анальгетика Тафалгина у онкологических пациентов с хроническим болевым синдромом (ХБС), подтвердить гипотезу о неменьшей эффективности Тафалгина в сравнении с морфином. МАТЕРИАЛ И МЕТОДЫ На базе 5 клинических центров проведено открытое сравнительное многоцентровое рандомизированное клиническое исследование III фазы по изучению эффективности и безопасности Тафалгина у онкологических пациентов с ХБС. Пациенты рандомизированы в две группы: 1-я группа (n=120) получала только Тафалгин подкожно; 2-я группа (n=59) — таблетки морфина 28 дней (период 1) и далее Тафалгин 28 дней (период 2). Первичной конечной точкой эффективности была частота сохранения ответа на обезболивающую терапию к 28-му дню. ХБС оценивали по цифровой рейтинговой шкале (NRS 0/10 баллов); по 5-балльной шкале Лайкерта для пациентов и врачей; по опроснику качества жизни SF-36. Анализ безопасности проводили на основании оценки частоты и выраженности нежелательных явлений (НЯ). РЕЗУЛЬТАТЫ Всего обследовано 179 пациентов (популяция ITT); завершили обследование 143 пациента (популяция PP). В 1-й группе доля пациентов с сохранением ответа на обезболивающую терапию к 28-му дню составила 98,97%, во 2-й группе — 100,00% (p=0,6783) для популяции РР. Для популяции ITT: в 1-й группе доля пациентов с сохранением ответа на обезболивающую терапию к 28-му дню была 84,17%, во 2-й группе — 88,14% (p=0,4787). Не выявлено случаев неэффективной терапии Тафалгином. Среднее значение NRS в популяция PP в начале терапии составило 0,42±0,48 и 0,30±0,47 балла в 1-й и 2-й группах (p=0,1250); к 28-му дню — 0,38±0,44 и 0,28±0,30 балла в этих группах (p=0,3472). В популяции ITT: NRS исходно составил 0,53±0,61 и 0,51±0,81 балла в 1-й и 2-й группах, (p=0,3519); к 28-му дню — 0,54±0,81 и 0,41±0,50 балла соответственно, (p=0,4536). После перевода пациентов с морфина на Тафалгин сохранился адекватный контроль боли через 56 и 84 дня терапии. На фоне приема Тафалгина определялась меньшая частота возникновения НЯ. ЗАКЛЮЧЕНИЕ Тафалгин оказывает выраженное обезболивающее действие, не уступающее морфину при лечении онкологического ХБС, имеет благоприятный профиль безопасности и меньшую частоту НЯ относительно морфина.